Skip to main content
Premium Trial:

Request an Annual Quote

Geneva Bioinformatics, Waters, PerkinElmer


Geneva Bioinformatics said last week that it will be releasing Phenyx, a software platform for the identification of proteins and peptides from peptide mass fingerprinting and tandem-MS mass spectrometry data. GeneBio will collaborate with the Swiss Institute of Bioinformatics to offer the software to the scientific community.

Waters announced last week that it has begun shipping its new Aquity Ultra Performance LC liquid chromatography system. The LC system consists of a binary solvent manager, an optional sample manager, Aquity UPLC column chemistry, a column heater module, and a tunable UV and/or photodiode array detectors. The sample organizer has a capacity of up to 21 microtitre plates or up to eight vial racks. The system is controlled by Waters Empower or MassLynx chromatography/mass spectrometry software.

PerkinElmer said last week that the US Food and Drug Administration has approved its new tandem mass spectrometry kit that screens for over 40 disorders in newborns with one heel-stick blood sample. the company said that the kit, called the NeoGram Amino Acids and Acylcarnitines Tandem Mass Spectrometry Kit, is the first newborn screening kit to use tandem MS.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.